Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer

Table 3

Summary of 5 years survival segregated by intrinsic subtypes.

	ER+, HER2− (%)	ER−, HER2− (%)	ER+, HER2+ (%)	ER−, HER2+ (%)
DFS
psCR	92	83	100	93
No pCR	70	61	77	52
OS
pCR	96	91	100	93
No pCR	88	72	91	74

ER, estrogen receptors; PR, progesterone receptors; HER, human epidermal growth factor receptor 2; pCR, pathological complete response; DFS, disease-free survival; OS, overall survival.